http://exhibits.library.stonybrook.edu/mfp/files/original/b7b9125005e38925dad9724a992acc02.pdf f0a19306cccf116a256fd25218ad0b6d PDF Text Text April Fred Clark, M. D. Robins Cb. 1407 Cummings Drive I], 1972 A. H. ﬁichmondL Virginia Be; Labelling of Butaperasine (Repoise) Dear Fred, I am pleased to answer the inquiry regarding the labelling of.Repoise (butaperasine), limiting its application to patients with chronic mental disorders. I have studied butaperasine since 1964, assessing the clinical effects in chronic schizophrenic patients; the EEC and clinical relations; the effects of'concentrate (syrup) Repcise in acute mentally and in association with Dre. Itil and Holden at the Missouri ill; Institute of‘Psychiatry, have been acquainted with their data on the effects on clinical laboratory tests and the EKG. In these studies, and in reading the published data, we to be an effective antipsychotic agent with a low profile of'extrapyramidal effects. Dosages can be increased rapidly and the therapeutic effect can often be observed in 3 to 4 days. In its EEC profile, putaperasine exhibits a characteristic hypersynchrony of alpha activity, enhanced amplitudes, decreased variability of'frequencies, and in higher dosages, enhanced theta and delta activity with a reduction in fast frequencies. This profile is similar to piperasine phenothiaaines, such as fluphenasine. have found butaperasine In the clinical studies, its activity is similar to fluphenasine, in acute and chronic cases. From this point of’view, the implied limitation to chronic cases appears arbitrary: fhe difficulties in differential diagnosis is great, and is it often impossible to decide whether the patient is acutely ill, a relapse in a chronic illness, or an acute exacerbation in the course cf'a chronic illness. both Zhe symptomatic is not specific these the limitation is response to phenothiasines for schizophrenia, but is related to the symptom complex. we view acting in a non-specific fashion, and thus arbitrary. For example, patients with anxiety often show a reduction in this symptom, regardless whether the symptom is part of'schisophrenia compounds as �_ .~ .w . ,_. , . r -7. ”y, “.2“, .,. 7..., ... .- .w “my...“ , .'.- .1, v m._ N wwrv T, w....,....,., 1.....vww-sw. »—.=- a...“ w 3., -- n .- .._. ,. ..- . .7 PW -, m,:'dﬁlw “Veqrvxv .rr.w . . . . gnaw v<,."'l).‘5a . W'WW" ~,— NW. . or a part of an anxiety syndrome; similarly, the sypptom of psychomotor agitation often responds whether in schizophrenia, depressive psychosis, or senile agitation. In my experience the decision to use a therapeutic agent on a clinical diagnosis, but on a symptom profile, is usually based not it and some elements of history. From this point of view, seems arbitrary and an unnecessary implied limitation on the decisions of the physician to continue the labelling restriction for Repoise for chronic cases. From another point of view, the limitation restricts the teaching of the use of Repoise. In teaching residents the principles of psychopharmacology, it is a special burden for the teacher to attempt to describe the use of butaperazine and note its limitations. It is much easier to recomend the use of fluphenazine, for which no such limitation is implied (and incidentally, for which a variety of form- ulations exist). I trust these comments are useful. Sincerely yours, Max Fink, M. D. Professor of Psychiatry Ref: Therapeutic Studies in THerapy Resistant Schizophrenic Patients. Cbﬂg. Psychiat. Z;488-493, 1966. Clinical Laboratory Test Standards in New Drug Trials. 1—8, 1967. J. Clin. Pharm. & New Drugs, _7_: Organic Treatment of Schizophrenia. In: A.Freedmand& H. Xaplan (Eds.), Williams pp. 661-664, 1967. Textbook & of Psychiatry, Wilkins, Baltimore, Treatment of Chronic Psychotic Patients with Combined Medications. Neuropsychopharmacology, Excerpta Medica, Amsterdam, 101601020,1967. Differentiation of Psychotropic 9:267-—280, 1968. Drugs by EEG Analysis, Aggressoloﬂe Liquid Butaperasine (Repoise) in the Treatment Mental Health Clinic. Curr. THerap. Research of Psychosis in a _1__1_: 57~63, 1969. .<~.'—VI'.A.\ � Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Correspondence to: Clark, Fred Type The nature or genre of the resource Text Identifier An unambiguous reference to the resource within a given context mfp-05-00-026-2-206 Date A point or period of time associated with an event in the lifecycle of the resource 1972 Creator An entity primarily responsible for making the resource <a title="Fink, Max, 1923-" href="http://id.loc.gov/authorities/names/n79039548" target="_blank">Fink, Max, 1923-</a> Subject The topic of the resource Correspondence -- Correspondence Relation A related resource The Max Fink Collection Description An account of the resource Rights Information about rights held in and over the resource <a title="IN COPYRIGHT - EDUCATIONAL USE PERMITTED" href="http://rightsstatements.org/vocab/InC-EDU/1.0/" target="_blank">IN COPYRIGHT - EDUCATIONAL USE PERMITTED</a> Source A related resource from which the described resource is derived Special Collections and University Archives, University Libraries. Stony Brook University Libraries (State University of New York). Language A language of the resource en-US Format The file format, physical medium, or dimensions of the resource application/pdf Publisher An entity responsible for making the resource available Contributor An entity responsible for making contributions to the resource Correspondence